Fisher & Paykel (ASX:FPH) Reports Profit Of $121.2 Million, Up 24%

Fisher & Paykel Healthcare (ASX:FPH) has reported its half year result to 30 September 2019. 

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

Fisher & Paykel Healthcare

online pharmacy purchase lioresal online no prescription
online pharmacy vibramycin no prescription pharmacy

(ASX: FPH) has reported its half year result to 30 September 2019.

Fisher & Paykel Healthcare Corp is a manufacturer, designer and marketer of products & systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The company has been operating in the healthcare industry since the 60s. The healthcare business has been a separate entity since 2001 when the company split from its appliances business.

FY20 Half Year Result

The healthcare business reported that in the half year period it grew operating revenue by 12%, or 9% in constant currency terms, to $570.9 million (all amounts are in New Zealand dollars).

It reported faster growth for its hospital operating revenue, it grew by 19%, or 17% in constant currency. Management attributed some of this result to an extended flu season in the US.

There was 23% constant currency revenue growth for new applications consumables, which are products used in non-invasive ventilation, Optiflow nasal high flow therapy, and surgical applications. The benefits continue to flow from the growing body of clinical research in the use of nasal high flow therapy.

There was 2% growth in homecare operating revenue (1% decline in constant currency) and a 1% decline in constant currency revenue in OSA masks.

Thanks to growth of higher profit products, the gross margin increased by 26 basis points (0.26%) to 67.1% which helped net profit rise by 23% to $121.2 million

Fisher & Paykel Dividend

The Board decided to declare an interim dividend of 12 cents per share, an increase of 23% compared to last year.

FY20 Outlook

online pharmacy https://doctordogsroselle.com/css/spiriva.html no prescription pharmacy

The company is expecting consistent underlying trends in the hospital product segment. Assuming a moderate flu season in FY20, growth in the second half of FY20 will be similar to the growth in FY19.

Homecare revenue in FY20 is expected to be similar to FY19 in constant currency terms.

Full year operating revenue is expected to be $1.19 billion and net profit after tax is predicted to be in a range of $255 million to $265 million.

[ls_content_block id=”14947″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

CSL, Xero, ANZ... the ASX is beaten up

Right now, only brave investors are buying. Is ASX Reporting Season your KEY opportunity to act? Buy, or sell.

This coming Monday night, our two most experienced professional investors, Owen Rask and Leigh Gant, are hosting an exclusive and rare webinar on the what to watch this ASX reporting season. LIVE and free

With over 35 years of combined investing experience, join our Chief Investment Officer and Head of Content for our free Q&A.

We’ll be diving into results from CSL, Pro Medicus (ASX: PME), ANZ Bank and more. It’s absolutely free to join us. Take advantage of this volatility with our free playbook. Simply click here to view the topics.

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.